Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that activating the PPARγ-LIFR-STAT3 axis drives hepatic stellate cell senescence, highlighting a potential therapeutic target for liver fibrosis.
Liver fibrosis represents a major unmet clinical challenge, and induction of hepatic stellate cell (HSCs) senescence has emerged as a promising therapeutic strategy to halt or reverse fibrotic progression. PPARγ is a key regulator of HSCs quiescence; however, the downstream molecular mechanisms mediating its pro-senescence effects remain poorly defined. Here, we demonstrate that PPARγ expression is markedly reduced in a CCl₄-induced mouse liver fibrosis model and that its restoration drives HSC inactivation and senescence. Through integrated bioinformatics analysis and functional validation in PPARγ-overexpressing HSC-T6 cells, we identified leukemia inhibitory factor receptor (LIFR) as a direct transcriptional target of PPARγ. Mechanistically, PPARγ upregulates LIFR to suppress STAT3 phosphorylation, thereby downregulating fibrosis markers CO Ⅰ and α-SMA, elevating P21 and γ-H2A.X, and reducing CCND1. Crucially, LIFR knockdown abolished all PPARγ-mediated effects, confirming its indispensable role in this axis. Furthermore, combined treatment with the STAT3 inhibitor WP1066 synergistically enhanced PPARγ-driven HSC senescence in a LIFR-dependent manner. These findings establish a PPARγ-LIFR-STAT3 signaling cascade as a critical regulator of HSCs fate, and suggest that pharmacological activation of this axis represents a tractable approach for fibrosis resolution.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: